Gemcitabine elaidate
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Gemcitabine elaidate
- Molecular weight
- 527.65
- Structure (SMILES)
- CCCCCCCC/C=C/CCCCCCCC(=O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O
- 2 deoxy 2 2 difluorocytidine 5 9e octadec 9 enoate
- 2'-DEOXY-2',2'-DIFLUOROCYTIDINE 5'-(9E)-OCTADEC-9-ENOATE
- 5 o trans 9 octadecenoyl 1 beta d 2 deoxy 2 2 difluorocytidine
- 5'-O-(TRANS-9''-OCTADECENOYL)-1-.BETA.-D-2'DEOXY-2',2'-DIFLUOROCYTIDINE
- co 1 01
- co 1 01 and cisplatin
- co 101
- CO-1.01
- CO-101
- cp 4126
- CP-4126
- elaidate de gemcitabine
- Elaidate de gemcitabine
- elaidato de gemcitabina
- Elaidato de gemcitabina
- gemcitabine elaidate
- Gemcitabine elaidate
- gemcitabine elaidate [INN]
- GEMCITABINE ELAIDATE [USAN]
- Gemcitabine elaidate [WHO-DD]
- gemcitabine elaidate inn
- gemcitabine elaidate usan
- gemcitabine elaidate who dd
- iv cp 4126
- IV CP-4126
- CAS registry numbers
- 210829-30-4
- ChEMBL ID
- CHEMBL3039516
- InChIKey
- HESSNRGIEVBPRB-QDDPNBLJSA-N
- PubChem compound IDs
- 9828310
- FDA ingredient codes (UNII)
- 231C73W7LG
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -citabine
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0003860
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000359
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021040
- Highest recorded phase
- 2
- NCT00778128
- NCT01392976
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 2
- Polar surface area
- 116.67
- Calculated partition coefficient (ALogP)
- 5.3
- Calculated partition coefficient (XLogP)
- 6.2
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 18
- Heavy atoms
- 37
- Molecular formula
- C27H43F2N3O5
- Monoisotopic mass
- 527.31707780
- Natural product
- No
- Recorded assays
- 124
- Active assays
- 100
Active assay types
- Confirmatory
Related records
Trials (33)
- A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin
- A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
- A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
- A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
- A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
- A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
- A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
- A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
- ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC
- Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
- Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
- Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer
- EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients
- Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
- Gemcitabine With Curcumin for Pancreatic Cancer
- Gemcitabine With or Without Capecitabine in Treating Patients With Advanced Pancreatic Cancer
- Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
In development for (5)
- Malignant pancreatic neoplasm Phase 2
- Neoplasm Phase 1
- Non-small cell lung carcinoma Phase 1
- Pancreatic adenocarcinoma Phase 2
- Pancreatic neoplasm Phase 2